Unlock instant, AI-driven research and patent intelligence for your innovation.

Application and kit of miRNA markers in the preparation of products for the evaluation of the efficacy of olanzapine in the treatment of schizophrenia

A technology for schizophrenia and efficacy evaluation, applied in biochemical equipment and methods, and microbial determination/examination, etc., can solve problems such as adverse reactions and rebound of positive symptoms

Active Publication Date: 2021-09-28
SHANGHAI JIAOTONG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In terms of tolerability and safety, compared with traditional antipsychotic drugs, olanzapine has a better effect on psychosis, but some adverse reactions still inevitably occur
Clinical studies have pointed out that long-term use of olanzapine can induce energy metabolism syndromes such as drowsiness, weight gain, and hyperglycemia to a certain extent. Not only that, but some patients with effective early medication have positive symptoms rebound after continuous medication for a period of time, and Increasing the dosage cannot be reversed, that is, olanzapine resistance occurs. Therefore, it is necessary to develop a sensitive and specific biomarker to improve the diagnostic reliability of schizophrenia, so that targeted Carry out drug intervention and carry out clinical scientific research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application and kit of miRNA markers in the preparation of products for the evaluation of the efficacy of olanzapine in the treatment of schizophrenia
  • Application and kit of miRNA markers in the preparation of products for the evaluation of the efficacy of olanzapine in the treatment of schizophrenia
  • Application and kit of miRNA markers in the preparation of products for the evaluation of the efficacy of olanzapine in the treatment of schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1: High-throughput sequencing screening of miRNA markers related to the efficacy of olanzapine in the treatment of schizophrenia

[0057] 1. Screening of miRNA markers in peripheral blood related to the efficacy of olanzapine in the treatment of schizophrenia

[0058] 1.1. Serum sample processing, blood collection, centrifugation, and storage for later use

[0059] Peripheral blood of 10 schizophrenic patients who failed olanzapine treatment and 10 schizophrenic patients who were effective olanzapine treatment were collected. The patients all gave informed consent, and all the above specimens were obtained with the approval of the organizational ethics committee. All included subjects took 3ml of fasting venous blood in the morning, and immediately separated the serum by centrifugation at 2000rpm for 8min in a horizontal centrifuge, put the aspirated supernatant in a centrifuge tube, and centrifuged at 14000rpm for 10min at 4°C, and put the aspirated supernatant...

Embodiment 2

[0079] Example 2: qRT-PCR verification of expression differences of miR-143-3p

[0080] 2.1. Serum sample processing, blood collection, centrifugation, and storage for later use

[0081] Among the patients in Example 1, 4 cases of peripheral blood were collected from patients with schizophrenia who were ineffective in the treatment of olanzapine and 4 cases in each of patients with schizophrenia who were effective in the treatment of olanzapine, and the rest of the operations were the same as in Example 1;

[0082] 2.2. Extraction of total RNA

[0083] Total RNA extraction steps are the same as in Example 1;

[0084] 2.3. Use ultra-micro spectrophotometer to detect the quality of RNA

[0085] Take 2 ul of dissolved RNA, and measure the absorbance at 260 mm with an ultramicro spectrophotometer to calculate the yield of RNA.

[0086] 2.4. Perform reverse transcription to obtain cDNA, and perform fluorescence quantitative detection on the obtained cDNA;

[0087] The primers o...

Embodiment 3

[0107] Example 3: Research on the differential expression of miR-143-3p gene in other neural cell lines

[0108] 3.1. Cell culture

[0109] Inoculate human neuroblastoma cells (SH-SY5Y cells) in 6-well cell culture plates, add MEM:F12 medium containing 10% fetal bovine serum, and place in an incubator at 37°C, 5% CO2 and saturated humidity In , cells in the logarithmic growth phase were used for the experiment. When the degree of confluence is about 80%. SH-SY5Y cells were treated with olanzapine at concentrations of 0 μM (control group), 1 μM, and 10 μM for 24 hours.

[0110] 3.2. Extraction of RNA

[0111] (1) Aspirate the medium in the well plate, wash it twice with PBS, add 1mL Trizol to each well and pipette repeatedly for 10-15 times, then let stand at room temperature for 5 minutes;

[0112] (2) Collect the cell suspension into a 1.5mL enzyme-free EP tube, vortex for 10s, and then let it stand on ice for 5min; add 200μL of pre-cooled chloroform to each tube, shake i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application and a kit of a miRNA marker in the preparation of products for evaluating the curative effect of olanzapine in treating schizophrenia, the miRNA marker is miR-143-3p, and a method for detecting the expression level of miR-143-3p : Treatment of serum samples, blood collection, centrifugation, and storage for later use; extraction of total RNA; detection of the total amount of RNA using an ultra-micro spectrophotometer; reverse transcription to obtain cDNA, and quantitative detection of the obtained cDNA by fluorescence; relative quantitative method Analyze the test results. The present invention discovers for the first time that miR‑143‑3p is differentially expressed in the curative effect of olanzapine in the treatment of schizophrenia. By detecting the expression level of miR‑143‑3p, it is possible to judge the level of the curative effect of olanzapine in the treatment of schizophrenia, which can be used as The detection or treatment indicators are applied clinically to provide a theoretical basis for the mechanism research and clinical application of schizophrenia.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to the application and kit of a miRNA marker in the preparation of products for the evaluation of the curative effect of olanzapine in treating schizophrenia, especially a kind of miRNA marker for the curative effect of olanzapine in schizophrenia The application, detection method and kit of the evaluated peripheral blood miRNA marker miR-143-3p. Background technique [0002] Schizophrenia (SZ) is one of the most serious mental disorders, with positive symptoms such as hallucinations, delusions, and psychomotor excitement and / or negative symptoms such as blunt affect, apathy, social withdrawal, and decreased will. Clinical features. At present, Jingfen is facing two dilemmas of "difficult to diagnose and difficult to treat", which has brought an extremely heavy burden to individuals, families and society. Effective prevention and treatment of this disease is imminent. [0003]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12Q1/6851
CPCC12Q1/6883C12Q1/6851C12Q2600/158C12Q2600/178C12Q2600/106C12Q2600/166C12Q2521/107C12Q2531/113C12Q2545/101C12Q2563/107Y02A50/30
Inventor 秦胜营孙竞贺林
Owner SHANGHAI JIAOTONG UNIV